Event coverage & on-site insights

SHERIDAN, WYOMING - December 26, 2025 - Yokohama Rubber is leveraging the global reach of the Gymkhana stunt-film franchise to spotlight its ADVAN flagship performance tires, with the latest episode "Gymkhana: Aussie Shred" showcasing ADVAN-equipped Subaru machinery and racking up more than 5.3 million views in its first week online.

ADVAN brand visibility in a high-impact global stunt platform

The new film, released on Hoonigan Media Machine's official YouTube channel on December 9, 2025, is the third consecutive Gymkhana installment to feature ADVAN tires as original equipment on the lead vehicle.
Co-produced by Hoonigan Media Machine, 321 Action Action and Subaru Motorsports USA, the series has become a global benchmark for extreme driving content, delivering sustained visibility for tire and performance brands among highly engaged enthusiasts.

SHERIDAN, WYOMING - December 18, 2025 - Citroën is using the 2026 Brussels Motor Show as a strategic showcase for its renewed electric portfolio and brand positioning, placing compact EV innovation, comfort-led SUVs and electric motorsport on the radar of European dealers, fleet buyers and mobility partners.

Brussels stand becomes a live lab for Citroën's electrification strategy

At the show, which opens to the public on 9 January 2026, Citroën is building a stand that mirrors its current transformation: colourful, modern and highly focused on accessible, electrified mobility. Alongside the world premiere of the ELO concept, visitors will see the new C5 Aircross as the brand's flagship SUV, the Ami in its new Dark Side edition, and a Formula E single-seater that signals Citroën's next era in electric motorsport.

For B2B stakeholders, the line-up illustrates how Citroën is repositioning its range around:

SHERIDAN, WYOMING - December 18, 2025 - A new B2B-focused nautical event, the Napoli Boat Show (NBS), will debut from March 18-22, 2026 at Marina di Stabia in Castellammare di Stabia, positioning itself as a "Boutique Boat Show" built around a simple commercial premise: every boat on display is ready to sail, and sea trials are the norm rather than the exception.

A "Ready-to-Sea" exhibition model built for sales conversations
Unlike traditional dockside showcases, NBS is designed to reverse exhibition logic by putting on-water testing at the center of the buying process. The show's proposition is that there is a material difference between viewing a vessel moored at the quay and experiencing it underway-especially in a setting that allows shipowners and professional buyers to evaluate handling, comfort, and performance in real conditions.

SHERIDAN, WYOMING - December 15, 2025 - Dubai Airshow 2025 opened at Dubai World Central with the Middle East debut of two of China's homegrown C919 aircraft, signaling a higher-profile push by Chinese aerospace players to showcase commercial, unmanned, and next-generation aviation technologies to global buyers.

C919 debut puts China's narrowbody on a new international stage
At the 19th edition of the Dubai Airshow, the appearance of the C919 marked its first showing in the Middle East, with a flight demonstration at the venue. The aircraft's presence matters beyond the air display: for airlines, lessors, MRO providers, and airport stakeholders, international showcases help shape early market perception around supply-chain maturity, support ecosystems, and longer-term export ambitions.

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.

SHERIDAN, WYOMING - December 10, 2025 - Hanwha Finance is sharpening its Middle East growth agenda as Chief Global Officer Dong-Won Kim used his opening address at Abu Dhabi Finance Week's Global Markets Summit to position South Korea-UAE financial collaboration as a long-term strategic pillar for both economies and a testbed for next-generation digital capital markets.

Strengthening a Korea-UAE "100-Year Partnership" Through Finance

Speaking in Abu Dhabi, Kim framed financial services as the connective tissue that will turn high-level Korea-UAE diplomacy into investable projects and new cross-border capital flows. He noted that "since the establishment of diplomatic relations in 1980, South Korea and the UAE have continuously expanded the scope of cooperation", and stressed that Hanwha Finance intends to help carry forward a "100-year partnership" between the two nations.

SHERIDAN, WYOMING - December 10, 2025 - From its position as a fast-rising global capital hub, Abu Dhabi is using Abu Dhabi Finance Week's Asset Abu Dhabi forum to redefine how institutional investors think about asset allocation, risk and long-term value creation in a volatile macro environment. Hosted by Abu Dhabi Global Market (ADGM), the event's second day brought together leading capital allocators, hedge fund managers, family office leaders and policymakers to assess emerging opportunities and the next frontier of asset management.

Abu Dhabi's regulatory platform moves into the global first rank

SHERIDAN, WYOMING - December 8, 2025 - ANGA COM 2026 is positioning itself as a central meeting point for Europe's broadband, media and connectivity ecosystem, adding new formats for municipalities, in-house networks and interactive round tables while confirming Federal Minister for Digital Transformation and Government Modernisation Dr. Karsten Wildberger as keynote speaker at the opening in Cologne on May 19, 2026.

Federal Minister Headlines Gigabit Summit at Opening

Federal Minister Dr. Karsten Wildberger will open ANGA COM 2026 with a keynote address and then join the traditional Gigabit Summit, where CEOs of leading German telecommunications companies debate the sector's most pressing challenges. His early confirmation underscores ANGA COM's role as a high-level platform where policy, regulation and industry strategy meet, bringing together the broader telecommunications sector with the digital media world.

SHERIDAN, WYOMING - December 8, 2025 - Days after Johnson & Johnson reported a mid-stage failure for its anti-tau antibody posdinemab, Eisai is using the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference to argue that tau is still a viable target-if drug designers hit the right part of the protein-while investors and scientists pivot their attention to inflammation and vascular pathways.

Anti-tau Setbacks Raise the Bar for New Entrants

Tau-directed drugs have been among the most high-profile disappointments in Alzheimer's disease (AD) R&D. J&J's recent miss with posdinemab follows last year's Phase II failure of UCB's bepranemab and Eli Lilly's inability to replicate its amyloid success with the anti-tau candidate LY3372689. Collectively, these readouts have fed a narrative that tau may be an intractable or poorly understood target for disease modification.